Anke Biotechnology: may explore the business expansion of CD7-CAR-T through external authorization or cooperative development.

In the interactive platform, Bosunji's CD7-CAR-T pending product plans to attempt direct listing application in Belt and Road countries after approval. As for European and American countries, Bosunji company has communicated with the US Food and Drug Administration, and may use Chinese clinical data to directly apply for registration for Phase II clinical trials in the United States, and conduct Phase II clinical trials in the United States through partners. In terms of business expansion, it may be carried out through external licensing or cooperative development.